The St. Louis-based healthcare giant reported total revenues of $53.6 billion for the quarter ending June 30, a 4% increase driven by premium growth and higher membership in its Prescription Drug Plan business. Chief Executive Officer Sarah M. London noted that the results mark a milestone in the company’s ongoing strategy to restore profitability while maintaining a competitive cost structure.
A key driver of the improved performance was the company’s health benefits ratio, which fell to 89.6% from 93.0% in the second quarter of 2025. This improvement was largely fueled by more effective pricing in the Marketplace segment and disciplined management of medical cost trends within its Medicaid division. The company also successfully reduced its SG&A expense ratio to 7.0%, benefiting from cost-management initiatives and operational efficiencies.
Following these results, Centene updated its 2026 financial outlook. The company now expects adjusted diluted earnings per share to exceed $4.80, up from previous projections. The firm also increased its total revenue guidance to a range between $193.5 billion and $197.5 billion. During the quarter, Centene continued to strengthen its balance sheet, repurchasing $260 million in senior notes and maintaining a robust cash position of $44.8 billion in investments and restricted deposits.
Comments (0)
No comments yet. Be the first!